U.S. markets open in 3 hours 26 minutes

Anika Therapeutics, Inc. (ANIK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.25+0.04 (+0.17%)
At close: 04:00PM EST
24.25 0.00 (0.00%)
Pre-Market: 05:09AM EST

Anika Therapeutics, Inc.

32 Wiggins Avenue
Bedford, MA 01730
United States
781 457 9000

IndustryMedical Instruments & Supplies
Full Time Employees345

Key Executives

NameTitlePayExercisedYear Born
Dr. Cheryl Renee Blanchard Ph.D.President, CEO & Director1.31MN/A1964
Mr. Michael L. LevitzExecutive VP, CFO & Treasurer710.6kN/A1974
Mr. David Colleran J.D.Executive VP, General Counsel & Corporate Secretary664.54kN/A1972
Ms. Anne NunesSenior VP & COON/AN/A1969
Mr. Ian W. McLeodVP & Chief Accounting OfficerN/AN/AN/A
Mr. Mark NamaroffExecutive Director of Investor Relations & Corporate CommunicationsN/AN/A1963
Mr. James ChaseSenior Vice President of International Sales & MarketingN/AN/AN/A
Mr. Ben JosephVice President of Commercial & Corporate DevelopmentN/AN/AN/A
Ms. Lisa FunicielloVice President of Human ResourcesN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Corporate Governance

Anika Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2024 is 4. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.